Bioscience Company Announces Major Merger Agreement

On July 12th, Aditxt, Inc. (NASDAQ: ADTX), alongside its wholly owned subsidiary Adifem, Inc., and Evofem Biosciences, Inc. (OTCQB: EVFM), announced an amendment and restatement of their Merger Agreement. This revised agreement addresses several key pre-closing issues deemed essential for Evofem’s future success, including interim financing needs. Among the notable revisions is the substitution of cash for Aditxt’s common stock as the consideration for Evofem’s common stock in the merger. The parties involved are working diligently to close the transaction within the second half of 2024. $Aditxt (ADTX.US)$